Use of anti-osteoporotic drugs in central Norway after a forearm fracture
- 387 Downloads
Use of anti-osteoporotic drugs (AOD) the first year after a forearm fracture in central Norway was low in the period 2005–2012. Women with fractures used more AOD compared to the general population only in 2006, 2007, and 2011. Female gender, age ≥ 60 years, use of glucocorticosteroids, or ≥ 4 different drugs were associated with AOD use.
The primary aim of this study was to examine time trends in prevalence and incidence of AOD use the first year after a forearm fracture from 2005–2012. Further, secondary aims were to investigate if gender, the number of drugs used before fracture, or use of glucocorticoids influenced the prescription of AOD, and to examine adherence to AOD.
Data is from the fracture registry in Nord-Trøndelag and the Norwegian Prescription database, including women (N = 1434) and men (N = 513) 40–84 years with their first forearm fracture between 2005 and 2012. AOD were defined as bisphosphonates, teriparatide, denosumab, and raloxifene. Prevalence and incidence were calculated, and prevalent use among women with forearm fracture was compared with the population in Nord-Trøndelag and Norway. Age-adjusted Poisson regression analyses for time trends and odds ratio for treatment with AOD was estimated. Adherence was defined as medication possession ratio ≥ 80 %.
The first year after the fracture, 11.2 % of the women and 2.7 % of the men were prevalent users, while 5.1 % and 1.2 %, respectively, were incident users of AOD. Bisphosphonates comprised 98.8 %. AOD use among women with fractures was significantly higher compared to the general population in Nord-Trøndelag only in 2006, 2007, and 2011. There was a trend towards a decline in AOD use among women with fractures from 2005 to 2012 (coefficient −0.05, p = 0.15). Female gender, age ≥ 60 years, use of glucocorticosteroids, or ≥ 4 different drugs the last year before fracture were associated with AOD use.
In women, 54.8 % were adherent during 3 years after fracture.
The use of AOD after a forearm fracture was low. An increased focus on osteoporosis in fracture patients is needed for secondary fracture prevention.
KeywordsForearm fracture Osteoporosis Anti-osteoporotic drugs Bisphosphonates Glucocorticoids
The Fracture Register in Nord-Trøndelag was established by The Nord-Trøndelag Hospital Trust. The work was supported by the Liaison Committee between the Central Norway Regional Health Authority (RHA) and the Norwegian University of Science and Technology (NTNU).
Conflicts of interests
BA has received research grants from or served as a principal investigator in studies funded by Novartis, Nycomed/Takeda, NPS Pharmaceuticals, and Amgen. US has received research grants from or served as a principal investigator in studies conducted by Amgen, Eli Lilly, Novartis, Merck, and Wyeth pharmaceuticals. MH, SS, HM, AJS, AL, and BS have no disclosures.
- 1.Singer A, Exuzides A, Spangler L, O'Malley C, Colby C, Johnston K, Agodoa I, Baker J, Kagan R (2015) Burden of illness for osteoporotic fractures compared with other serious diseases among postmenopausal women in the United States. Mayo Clin Proc 90(1):53–62. doi: 10.1016/j.mayocp.2014.09.011 PubMedCrossRefGoogle Scholar
- 3.(1993) Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 94 (6):646–650Google Scholar
- 8.Hansen L, Petersen KD, Eriksen SA, Langdahl BL, Eiken PA, Brixen K, Abrahamsen B, Jensen JE, Harslof T, Vestergaard P (2015) Subsequent fracture rates in a nationwide population-based cohort study with a 10-year perspective. Osteoporos Int 26(2):513–519. doi: 10.1007/s00198-014-2875-2 PubMedCrossRefGoogle Scholar
- 9.Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P, Eisman J, Fujiwara S, Garnero P, Kroger H, McCloskey EV, Mellstrom D, Melton LJ, Pols H, Reeve J, Silman A, Tenenhouse A (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35(2):375–382. doi: 10.1016/j.bone.2004.03.024 PubMedCrossRefGoogle Scholar
- 12.Erny F, Auvinet A, Chu Miow Lin D, Pioger A, Haguenoer K, Tauveron P, Jacquot F, Rusch E, Goupille P, Mulleman D (2015) Management of osteoporosis in women after forearm fracture: data from a French health insurance database. Joint Bone Spine 82(1):52–55. doi: 10.1016/j.jbspin.2014.07.007 PubMedCrossRefGoogle Scholar
- 16.The Norwegian prescription database. The Norwegian Institute of Public Health. www.norpd.no.no
- 18.(2012) WHO collaborating centre for drug statistics methodology. Guidelines for ATC classification and DDD assignement. Norway: OsloGoogle Scholar
- 19.Regulations concerning food supplement in Norway (2004, revised 2014). https://lovdata.no/dokument/SF/forskrift/2004-05-20-755
- 27.Diamantopoulos AP, Rohde G, Johnsrud I, Skoie IM, Hochberg M, Haugeberg G (2012) The epidemiology of low- and high-energy distal radius fracture in middle-aged and elderly men and women in Southern Norway. PLoS One 7(8):e43367. doi: 10.1371/journal.pone.0043367 PubMedPubMedCentralCrossRefGoogle Scholar
- 30.Abrahamsen B, Jorgensen NR, Schwarz P (2015) Epidemiology of forearm fractures in adults in Denmark: national age- and gender-specific incidence rates, ratio of forearm to hip fractures, and extent of surgical fracture repair in inpatients and outpatients. Osteoporos Int 26(1):67–76. doi: 10.1007/s00198-014-2831-1 PubMedCrossRefGoogle Scholar
- 34.Crandall CJ, Newberry SJ, Diamant A, Lim YW, Gellad WF, Suttorp MJ, Motala A, Ewing B, Roth B, Shanman R, Timmer M, Shekelle PG (2012) Treatment to prevent fractures in men and women with low bone density or osteoporosis: update of a 2007 report. Rockville MDGoogle Scholar
- 36.Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster DW, Ebeling PR, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Howe TS, van der Meulen MC, Weinstein RS, Whyte MP (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 29(1):1–23. doi: 10.1002/jbmr.1998 PubMedCrossRefGoogle Scholar
- 37.Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S, Watts NB, Brandi ML, Peters E, Guise T, Eastell R, Cheung AM, Morin SN, Masri B, Cooper C, Morgan SL, Obermayer-Pietsch B, Langdahl BL, Al Dabagh R, Davison KS, Kendler DL, Sandor GK, Josse RG, Bhandari M, El Rabbany M, Pierroz DD, Sulimani R, Saunders DP, Brown JP, Compston J (2015) Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 30(1):3–23. doi: 10.1002/jbmr.2405 PubMedCrossRefGoogle Scholar
- 38.Norwegian guidelines for prevention and treatment of osteoporosis and osteoporotic fractures. (2005). http://helsedirektoratet.no/publikasjoner/nasjonal-faglige-retningslinje-for-forebygging-og-behandling-av-osteoporose-og-osteoporotiske-brudd
- 41.Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288(3):321–333PubMedCrossRefGoogle Scholar
- 44.Lekamwasam S, Adachi JD, Agnusdei D, Bilezikian J, Boonen S, Borgstrom F, Cooper C, Diez Perez A, Eastell R, Hofbauer LC, Kanis JA, Langdahl BL, Lesnyak O, Lorenc R, McCloskey E, Messina OD, Napoli N, Obermayer-Pietsch B, Ralston SH, Sambrook PN, Silverman S, Sosa M, Stepan J, Suppan G, Wahl DA, Compston JE (2012) A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int 23(9):2257–2276. doi: 10.1007/s00198-012-1958-1 PubMedCrossRefGoogle Scholar
- 45.Eisman JA, Bogoch ER, Dell R, Harrington JT, McKinney RE Jr, McLellan A, Mitchell PJ, Silverman S, Singleton R, Siris E (2012) Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention. J Bone Miner Res 27(10):2039–2046. doi: 10.1002/jbmr.1698 PubMedCrossRefGoogle Scholar